Case report: Transformative potential of trastuzumab deruxtecan in the first line treatment for advanced HER2-mutated lung adenocarcinoma: a case report and clinical insights

The treatment of non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma (LUAD), represents a significant oncological challenge due to its aggressive behavior, high metastatic potential and poor prognosis. HER2 mutation is a rare but critical oncogenic driver associated with resistance...

Полное описание

Библиографические подробности

Главные авторы:	Guanbin Huang, Tongtong Xia, Dongxiao Yang, Muwen Lin, Yiping Luo, Yuchan Li, Hualin Chen
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Frontiers Media S.A. 2025-04-01
Серии:	Frontiers in Pharmacology
Предметы:	HER2-mutant NSCLC trastuzumab deruxtecan antibody-drug conjugate first line treatment central nervous system metastases
Online-ссылка:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1564834/full
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!